Literature DB >> 22113518

The response to rapid infusion of fentanyl in the human brain measured using pulsed arterial spin labelling.

Fernando O Zelaya1, Evangelos Zois, Christopher Muller-Pollard, David J Lythgoe, Sarah Lee, Caroline Andrews, Trevor Smart, Patricia Conrod, William Vennart, Steven C R Williams, Mitul A Mehta, Laurence J Reed.   

Abstract

OBJECTIVE: We evaluated the sensitivity of pulsed Arterial Spin Labelling (pASL) for the detection of changes in regional cerebral blood perfusion (CBP) during and after intra-venous (i.v.) infusion of an opioid agonist (fentanyl) and an opioid antagonist (naloxone).
MATERIALS AND METHODS: Twenty-three subjects were scanned four times, receiving i.v. infusion of fentanyl, naloxone, placebo and a second fentanyl administration, in four separate scanning sessions in randomised order. End-tidal CO(2), respiration rate and heart rate were recorded continuously throughout each scan. pASL time series were collected using single shot EPI for 15 min (including 5 min of baseline prior to infusion).
RESULTS: Significant increases in CBP were detected during and after administration of fentanyl, (when compared to placebo and naloxone), in most areas of high concentration of mu-opioid receptors (thalamus, lingual gyrus, para-hippocampal gyrus, and insula); near-significant increases were also observed in the insula. No increases in perfusion were observed during or after naloxone infusion. No correlation was found between regional rCBF changes and end-tidal CO(2), respiration rate or heart rate. Good reliability was found between the first and second fentanyl sessions but the regions of high reliability did not overlap completely with those of highest perfusion change.
CONCLUSION: pASL is a suitable method for examining rapid, dynamic effects of opioid administration on brain physiology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22113518     DOI: 10.1007/s10334-011-0293-4

Source DB:  PubMed          Journal:  MAGMA        ISSN: 0968-5243            Impact factor:   2.310


  46 in total

1.  fMRI measurement of CNS responses to naloxone infusion and subsequent mild noxious thermal stimuli in healthy volunteers.

Authors:  M C Borras; L Becerra; A Ploghaus; J M Gostic; A DaSilva; R G Gonzalez; D Borsook
Journal:  J Neurophysiol       Date:  2004-06       Impact factor: 2.714

2.  Use of Positron Emission Tomography to Measure Brain Activity Responses to Fentanyl Analgesia.

Authors: 
Journal:  Curr Rev Pain       Date:  1999

Review 3.  Neuroscience of addiction.

Authors:  G F Koob; P P Sanna; F E Bloom
Journal:  Neuron       Date:  1998-09       Impact factor: 17.173

4.  Site of opioid action in the human brain: mu and kappa agonists' subjective and cerebral blood flow effects.

Authors:  T E Schlaepfer; E C Strain; B D Greenberg; K L Preston; E Lancaster; G E Bigelow; P E Barta; G D Pearlson
Journal:  Am J Psychiatry       Date:  1998-04       Impact factor: 18.112

5.  Remifentanil-induced cerebral blood flow effects in normal humans: dose and ApoE genotype.

Authors:  W Andrew Kofke; Patricia A Blissitt; Hengyi Rao; Jiongjiong Wang; Kathakali Addya; John Detre
Journal:  Anesth Analg       Date:  2007-07       Impact factor: 5.108

6.  Dopamine release in the human striatum: motor and cognitive tasks revisited.

Authors:  Julia M Lappin; Suzanne J Reeves; Mitul A Mehta; Alice Egerton; Mark Coulson; Paul M Grasby
Journal:  J Cereb Blood Flow Metab       Date:  2008-12-17       Impact factor: 6.200

7.  Increased cerebral perfusion in adult attention deficit hyperactivity disorder is normalised by stimulant treatment: a non-invasive MRI pilot study.

Authors:  Ruth L O'Gorman; Mitul A Mehta; Philip Asherson; Fernando O Zelaya; Keeley J Brookes; Brian K Toone; David C Alsop; Steven C R Williams
Journal:  Neuroimage       Date:  2008-04-20       Impact factor: 6.556

8.  Caffeine-induced uncoupling of cerebral blood flow and oxygen metabolism: a calibrated BOLD fMRI study.

Authors:  Joanna E Perthen; Amy E Lansing; Joy Liau; Thomas T Liu; Richard B Buxton
Journal:  Neuroimage       Date:  2007-11-12       Impact factor: 6.556

9.  Practice and difficulty evoke anatomically and pharmacologically dissociable brain activation dynamics.

Authors:  Ed Bullmore; John Suckling; Fernando Zelaya; Chris Long; Garry Honey; Laurence Reed; Carol Routledge; Virginia Ng; Paul Fletcher; John Brown; Steve C R Williams
Journal:  Cereb Cortex       Date:  2003-02       Impact factor: 5.357

10.  Acute effects of single-dose aripiprazole and haloperidol on resting cerebral blood flow (rCBF) in the human brain.

Authors:  Rowena Handley; Fernando O Zelaya; A A T Simone Reinders; Tiago Reis Marques; Mitul A Mehta; Ruth O'Gorman; David C Alsop; Heather Taylor; Atholl Johnston; Steve Williams; Philip McGuire; Carmine M Pariante; Shitij Kapur; Paola Dazzan
Journal:  Hum Brain Mapp       Date:  2012-03-25       Impact factor: 5.038

View more
  12 in total

1.  Arterial spin labeling: its time is now.

Authors:  David C Alsop
Journal:  MAGMA       Date:  2012-04       Impact factor: 2.310

2.  Phenomenologically distinct psychotomimetic effects of ketamine are associated with cerebral blood flow changes in functionally relevant cerebral foci: a continuous arterial spin labelling study.

Authors:  T A Pollak; S De Simoni; B Barimani; F O Zelaya; J M Stone; M A Mehta
Journal:  Psychopharmacology (Berl)       Date:  2015-10-05       Impact factor: 4.530

3.  Reproducibility of pharmacological ASL using sequences from different vendors: implications for multicenter drug studies.

Authors:  Henri J M M Mutsaerts; Rebecca M E Steketee; Dennis F R Heijtel; Joost P A Kuijer; Matthijs J P van Osch; Charles B L M Majoie; Marion Smits; Aart J Nederveen
Journal:  MAGMA       Date:  2015-01-15       Impact factor: 2.310

Review 4.  Effects of anesthesia on cerebral blood flow, metabolism, and neuroprotection.

Authors:  Andrew M Slupe; Jeffrey R Kirsch
Journal:  J Cereb Blood Flow Metab       Date:  2018-07-16       Impact factor: 6.200

Review 5.  Pathophysiological and clinical considerations in the perioperative care of patients with a previous ischaemic stroke: a multidisciplinary narrative review.

Authors:  Jatinder S Minhas; William Rook; Ronney B Panerai; Ryan L Hoiland; Phil N Ainslie; Jonathan P Thompson; Amit K Mistri; Thompson G Robinson
Journal:  Br J Anaesth       Date:  2019-12-06       Impact factor: 9.166

6.  The effect of morphine on regional cerebral blood flow measured by 99mTc-ECD SPECT in dogs.

Authors:  Antita Adriaens; Kathelijne Peremans; Tim Waelbers; Eva Vandermeulen; Siska Croubels; Luc Duchateau; André Dobbeleir; Kurt Audenaert; Jos Eersels; Simon Vermeire; Bart De Spiegeleer; Ingeborgh Polis
Journal:  PLoS One       Date:  2014-10-08       Impact factor: 3.240

7.  Pain facilitation brain regions activated by nalbuphine are revealed by pharmacological fMRI.

Authors:  Robert Gear; Lino Becerra; Jaymin Upadhyay; James Bishop; Diana Wallin; Gautam Pendse; Jon Levine; David Borsook
Journal:  PLoS One       Date:  2013-01-08       Impact factor: 3.240

8.  Quantifying the test-retest reliability of cerebral blood flow measurements in a clinical model of on-going post-surgical pain: A study using pseudo-continuous arterial spin labelling.

Authors:  Duncan J Hodkinson; Kristina Krause; Nadine Khawaja; Tara F Renton; John P Huggins; William Vennart; Michael A Thacker; Mitul A Mehta; Fernando O Zelaya; Steven C R Williams; Matthew A Howard
Journal:  Neuroimage Clin       Date:  2013       Impact factor: 4.881

9.  Reduction in cerebral perfusion after heroin administration: a resting state arterial spin labeling study.

Authors:  Niklaus Denier; Hana Gerber; Marc Vogel; Markus Klarhöfer; Anita Riecher-Rossler; Gerhard A Wiesbeck; Undine E Lang; Stefan Borgwardt; Marc Walter
Journal:  PLoS One       Date:  2013-09-10       Impact factor: 3.240

Review 10.  Imaging opioid analgesia in the human brain and its potential relevance for understanding opioid use in chronic pain.

Authors:  Michael C Lee; Vishvarani Wanigasekera; Irene Tracey
Journal:  Neuropharmacology       Date:  2013-07-25       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.